Global Alzheimer’s Therapeutics Market Overview:
According to SPER Market Research, the Alzheimer’s Therapeutics Market is estimated to reach USD 21.47 billion by 2032 with a CAGR of 16.4%.
A neurological condition called Alzheimer's disease results in the death of brain cells and brain shrinkage. It is the most prevalent kind of dementia that causes a person's capacity to operate independently to continuously deteriorate in their mental, behavioural, and social abilities. The disease's early symptoms include forgetting recent conversations or experiences. As the illness advances, a person with Alzheimer's will have significant memory loss and lose the capacity to do daily duties.The incidence of Alzheimer's disease is increasing in both developed and developing nations, which is a significant factor driving the growth of the global market for Alzheimer's therapies. The demand for developing therapies for Alzheimer's disease has also increased due to the rising incidence of the condition throughout the world and a few other factors, such as a rise in the number of individuals who have been diagnosed. The availability of medications like Aricept, Exelon, Memantine, and Razadyne for the treatment of Alzheimer's disease is another factor driving the market's expansion.
Due to the popularity of this medicine class among healthcare professionals, the cholinesterase inhibitors market segment held the majority of market share the previous year. The others sector, however, is anticipated to experience significant growth over the course of the projection period due to rising patient demand for medications to treat Alzheimer's disease as well as the upcoming introduction of several disease-modifying medicines.
Due to the surge in demand for medications like cholinesterase inhibitors and N-methyl D-aspartate antagonist receptors, which are conveniently available at retail pharmacies, the drug store and retail pharmacy segment has dominated the market. The number of persons with Alzheimer's disease is predicted to climb throughout the forecast period, and more people are turning to online pharmacies to obtain their medications since they are a handy option for working professionals, elderly people, and those with physical limitations. Additionally, there has been a huge growth in internet usage, making it simple to obtain prescription drugs online and expanding online businesses abroad.
Impact of COVID-19 on the Global Alzheimer’s Therapeutics Market The global market for Alzheimer's treatment has grown as a result of the COVID-19 pandemic. Patients with Alzheimer's disease were more likely to get the coronavirus. The prolonged lockdown consequently caused more severe neuropsychiatric symptoms. Consequently, there was a rise in the need for Alzheimer's therapies during the pandemic due to an increase in the incidence of COVID-19 infections in individuals with Alzheimer's disease.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Drug Class, By Distribution Channel, By Drug Name |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | AbbVie Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd, Biogen, Merck & Co. Inc., Cipla Ltd., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, Janssen Pharmaceuticals, Inc. , Lannett Inc., Lupin Ltd, Macleods Pharmaceuticals Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent pharmaceuticals ltd., Unichem laboratories ltd, Viatris Inc., Zydus Lifesciences Ltd (CADILA).
|
Global Alzheimer’s Therapeutics Market Segmentation:
By Drug Class: Based on the Drug Class, Global Alzheimer’s Therapeutics Market is segmented as; Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonist and Others.
By Distribution Channel: Based on the Distribution Channel, Global Alzheimer’s Therapeutics Market is segmented as; Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy.
By Drug Name: Based on the Drug Name, Global Alzheimer’s Therapeutics Market is segmented as; Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured combination of memantine and donepezil.
By Region: Due to a rise in the number of products getting approved by the US FDA, North America contributed for the largest market share for Alzheimer's therapies and is predicted to maintain its dominance over the projection period. Additionally, the expansion of research initiatives to create innovative pharmaceuticals in North American developed nations had a significant influence on the market's expansion. However, due to the surge in new technologies aiding in the treatment of Alzheimer's disease, Asia-Pacific is anticipated to see the greatest growth rate throughout the market forecast for Alzheimer's therapies.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Alzheimer’s Therapeutics Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Alzheimer’s Therapeutics Market, By Drug Class, 2019-2032 (USD Million)
6.1 Cholinesterase inhibitors
6.2 N-Methyl-D-Aspartate (NMDA) receptor antagonist
6.3 Others
7. Global Alzheimer’s Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)
7.1 Hospital Pharmacy
7.2 Drug Store and Retail Pharmacy
7.3 Online Pharmacy
8. Global Alzheimer’s Therapeutics Market, By Drug Name, 2019-2032 (USD Million)
8.1 Donepezil
8.2 Rivastigmine
8.3 Memantine
8.4 Galantamine
8.5 Manufactured combination of memantine and donepezil
9. Global Alzheimer’s Therapeutics Market, By Region, 2019-2032 (USD Million)
9.1 North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2 Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3 Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4 South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5 Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1 AbbVie Inc.
10.1.1 Company details
10.1.2 Financial outlook
10.1.3 Product summary
10.1.4 Recent developments
10.2 Amneal Pharmaceuticals Inc.
10.2.1 Company details
10.2.2 Financial outlook
10.2.3 Product summary
10.2.4 Recent developments
10.3 Aurobindo Pharma Ltd
10.3.1 Company details
10.3.2 Financial outlook
10.3.3 Product summary
10.3.4 Recent developments
10.4 Biogen, Merck & Co. Inc.
10.4.1 Company details
10.4.2 Financial outlook
10.4.3 Product summary
10.4.4 Recent developments
10.5 Cipla Ltd.
10.5.1 Company details
10.5.2 Financial outlook
10.5.3 Product summary
10.5.4 Recent developments
10.6 DAIICHI SANKYO COMPANY, LIMITED
10.6.1 Company details
10.6.2 Financial outlook
10.6.3 Product summary
10.6.4 Recent developments
10.7 Dr. Reddy's Laboratories Ltd
10.7.1 Company details
10.7.2 Financial outlook
10.7.3 Product summary
10.7.4 Recent developments
10.8 Eisai Co. Ltd.
10.8.1 Company details
10.8.2 Financial outlook
10.8.3 Product summary
10.8.4 Recent developments
10.9 Eli Lilly and Company
10.9.1 Company details
10.9.2 Financial outlook
10.9.3 Product summary
10.9.4 Recent developments
10.10 H. Lundbeck A/S
10.10.1 Company details
10.10.2 Financial outlook
10.10.3 Product summary
10.10.4 Recent developments
10.11 Janssen Pharmaceuticals, Inc.
10.11.1 Company details
10.11.2 Financial outlook
10.11.3 Product summary
10.11.4 Recent developments
10.12 Lannett Inc.
10.12.1 Company details
10.12.2 Financial outlook
10.12.3 Product summary
10.12.4 Recent developments
10.13 Lupin Ltd
10.13.1 Company details
10.13.2 Financial outlook
10.13.3 Product summary
10.13.4 Recent developments
10.14 Macleods Pharmaceuticals Ltd.
10.14.1 Company details
10.14.2 Financial outlook
10.14.3 Product summary
10.14.4 Recent developments
10.15 Novartis AG
10.15.1 Company details
10.15.2 Financial outlook
10.15.3 Product summary
10.15.4 Recent developments
10.16 Sun Pharmaceutical Industries Ltd.
10.16.1 Company details
10.16.2 Financial outlook
10.16.3 Product summary
10.16.4 Recent developments
10.17 Teva Pharmaceuticals Industries Ltd.
10.17.1 Company details
10.17.2 Financial outlook
10.17.3 Product summary
10.17.4 Recent developments
10.18 Torrent pharmaceuticals ltd.
10.18.1 Company details
10.18.2 Financial outlook
10.18.3 Product summary
10.18.4 Recent developments
10.19 Unichem laboratories ltd.
10.19.1 Company details
10.19.2 Financial outlook
10.19.3 Product summary
10.19.4 Recent developments
10.20 Viatris Inc.
10.20.1 Company details
10.20.2 Financial outlook
10.20.3 Product summary
10.20.4 Recent developments
10.21 Zydus Lifesciences Ltd (CADILA)
10.21.1 Company details
10.21.2 Financial outlook
10.21.3 Product summary
10.21.4 Recent developments